Moreover, the overexpression of RBM39 could promote the proliferation and migration of NSCLC cells, and the expression of RBM39 had no obvious correlation with tumor stage, gender, and age, which preliminarily revealed that RBM39 was expected to become a biomarker and potential therapeutic target for lung cancer [3]. This evidence concerns the gene RBM39 and lung cancer.